首页> 外国专利> Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer

Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer

机译:评估非小细胞肺癌患者的方法和成分

摘要

Methods, kits, devices, and computer systems are provided for obtaining an NSCLC marker level representation for an individual with non small cell lung carcinoma (NSCLC); and/or for providing a prognosis for an individual with NSCLC. The methods can include measuring expression levels, in a biological sample, of 2 or more NSCLC markers selected from: MAD2L1, GINS1, SLC2A1, KRT6A, FCGRT, TNIK, BCAM, KDM6A, and FAIM3; calculating an NSCLC marker level representation based on the measured expression levels; comparing the NSCLC marker level representation of the individual to a reference marker level representation; providing a prognosis based on the comparison; and/or generating a report that includes at least one of: (i) an NSCLC marker level representation, (ii) an NSCLC marker level representation and a reference NSCLC marker level representation, (iii) a prognosis, and (iv) guidance to a clinician as to a treatment recommendation based on the prognosis.
机译:提供了用于获得患有非小细胞肺癌(NSCLC)的个体的NSCLC标志物水平表示的方法,试剂盒,装置和计算机系统;和/或为NSCLC患者提供预后。该方法可以包括测量生物学样品中的两种或更多种选自以下的NSCLC标记的表达水平:MAD2L1,GINS1,SLC2A1,KRT6A,FCGRT,TNIK,BCAM,KDM6A和FAIM3;根据测得的表达水平计算NSCLC标志物水平的表达;比较个体的NSCLC标记水平表示与参考标记水平表示;根据比较结果提供预后;和/或生成包含以下至少一项的报告:(i)NSCLC标记水平表示,(ii)NSCLC标记水平表示和参考NSCLC标记水平表示,(iii)预后和(iv)指导临床医生根据预后的治疗建议。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号